Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (HALO)
NASDAQ:HALO
Holding HALO?
Track your performance easily
HALO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$33.15 - $65.53
Previous Close$47.16
Volume308.68K
Average Volume (3M)1.71M
Market Cap
$6.00B
Enterprise Value$6.84B
Total Cash (Recent Filing)$666.31M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)15.6
Beta1.19
Next Earnings
Feb 25, 2025EPS Estimate
$1.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.02
Shares Outstanding127,227,000
10 Day Avg. Volume1,615,338
30 Day Avg. Volume1,705,034
Standard Deviation0.13
R-Squared0.25
Alpha0.00781
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)13.25
Price to Sales (P/S)6.31
Price to Cash Flow (P/CF)13.00
P/FCF Ratio13.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue7.22
Enterprise Value/Gross Profit10.74
Enterprise Value/Ebitda11.85
Forecast
1Y Price Target
$63.29Price Target Upside33.13% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering9
Halozyme News
Bulls Say, Bears Say
Bulls Say
Market Growth PotentialENHANZE technology could help capture a large portion of the U.S. infusion therapy market and drive its growth.
Regulatory ApprovalHalozyme has amassed several regulatory approvals for its Enhanze-coformulated products, giving little reason to doubt the path forward to resolve the manufacturing facility issue in a timely fashion.
Royalty Revenue GrowthConfidence remains in Halozyme's ability to achieve significant growth in royalty revenue and adjusted EBITDA, with targets of over $1 billion by 2027.
Bears Say
Acquisition ChallengesEvotec's board of directors does not appear to be open to the proposal and has hired an investment bank to prepare a defense to Halozyme's takeover bid.
Financial PerformanceHalozyme shares are down approximately 18% since the rumor emerged regarding their intention to acquire Evotec.
Intellectual Property RisksThe European Patent Office has decided to revoke another of JNJ’s co-formulation patents for Darzalex Faspro, bringing attention to a non-zero longer-term risk to HALO’s European Faspro royalties.
---
Ownership Overview
0.99% Insiders
30.90% Mutual Funds
26.30% Other Institutional Investors
13.11% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HALO FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was $33.15 and its highest was $65.53 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is Feb 25, 2025 which is in 62 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Oct 31, 2024. The company reported $1.27 earnings per share for the quarter, beating the consensus estimate of $0.991 by $0.279.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is $1.15.
How many shares outstanding does Halozyme Therapeutics have?
Halozyme Therapeutics has 127,227,000 shares outstanding.
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of $1.27 in its last earnings report, beating expectations of $0.991. Following the earnings report the stock price went up 13.012%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Fisher Asset Management LLC. It holds Halozyme Therapeutics’s shares valued at 19M.
---
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
HALO Company Deck
---
HALO Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was largely positive, highlighting record revenue growth, successful new partnerships and approvals, and a positive outlook with increased guidance. A few challenges were noted, particularly around the MDASE platform and product sales fluctuations, but these were outweighed by the positive developments.Read More>---
HALO Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
HALO Stock 12 Month Forecast
Average Price Target
$63.29
▲(33.13% Upside)
Technical Analysis
Best Analysts Covering HALO
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+12.50%
reiterated a buy rating 7 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +12.50% per trade.
---